**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par ACO\_rate** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **ACO\_rate(Aneurysm complete occlusion rate at 6 months(Raymond score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 27 20.93 34.62 62.79 | 51 39.53 65.38 59.30 | 78 60.47 |
| **FRED X** | 16 12.40 31.37 37.21 | 35 27.13 68.63 40.70 | 51 39.53 |
| **Total** | 43 33.33 | 86 66.67 | 129 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par ACO\_rate*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.1459 | 0.7025 |
| **Test du rapport de vraisemblance** | 1 | 0.1465 | 0.7019 |
| **Khi-2 continuité ajustée** | 1 | 0.0365 | 0.8485 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.1448 | 0.7036 |
| **Coefficient Phi** |  | 0.0336 |  |
| **Coefficient de contingence** |  | 0.0336 |  |
| **V de Cramer** |  | 0.0336 |  |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 27 |
| **Pr <= F unilatérale à gauche** | 0.7155 |
| **Pr >= F unilatérale à droite** | 0.4261 |
|  |  |
| **Probabilité de la table (P)** | 0.1415 |
| **Pr <= P bilatéral** | 0.8487 |

|  |
| --- |
| ***Taille de l'échantillon = 129*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Aneurysm complete occlusion rate at 6 months(Raymond score)** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | No | 27 (34.6%) | 16 (31.4%) | 43 (33.3%) |
|  | Yes | 51 (65.4%) | 35 (68.6%) | 86 (66.7%) |
|  | 95% CI | 54.8% - 75.9% | 55.9% - 81.4% | 58.5% - 74.8% |
|  | Between group test |  |  | 0.702 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par ACO\_rateb** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **ACO\_rateb(Aneurysm complete occlusion rate at 6 months(OKM score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 9 20.93 32.14 69.23 | 19 44.19 67.86 63.33 | 28 65.12 |
| **FRED X** | 4 9.30 26.67 30.77 | 11 25.58 73.33 36.67 | 15 34.88 |
| **Total** | 13 30.23 | 30 69.77 | 43 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par ACO\_rateb*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.1389 | 0.7094 |
| **Test du rapport de vraisemblance** | 1 | 0.1405 | 0.7078 |
| **Khi-2 continuité ajustée** | 1 | 0.0006 | 0.9806 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.1356 | 0.7127 |
| **Coefficient Phi** |  | 0.0568 |  |
| **Coefficient de contingence** |  | 0.0567 |  |
| **V de Cramer** |  | 0.0568 |  |
| **WARNING: 25% des cellules ont un effectif théorique inférieur à 5. Le test du Khi-2 peut ne pas convenir.** | | | |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 9 |
| **Pr <= F unilatérale à gauche** | 0.7616 |
| **Pr >= F unilatérale à droite** | 0.4961 |
|  |  |
| **Probabilité de la table (P)** | 0.2578 |
| **Pr <= P bilatéral** | 1.0000 |

|  |
| --- |
| ***Taille de l'échantillon = 43*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Aneurysm complete occlusion rate at 6 months(OKM score)** | N | 28 |  | 28 |
|  | Missing data | 50 | 36 | 86 |
|  | No | 9 (32.1%) | 4 (26.7%) | 13 (30.2%) |
|  | Yes | 19 (67.9%) | 11 (73.3%) | 30 (69.8%) |
|  | 95% CI | 50.6% - 85.2% | 51.0% - 95.7% | 56% - 83.5% |
|  | Between group test |  |  | 1.000 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par AAO\_rate** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **AAO\_rate(Adequate occlusion rate at 6 months(Raymond score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 22 17.05 28.21 64.71 | 56 43.41 71.79 58.95 | 78 60.47 |
| **FRED X** | 12 9.30 23.53 35.29 | 39 30.23 76.47 41.05 | 51 39.53 |
| **Total** | 34 26.36 | 95 73.64 | 129 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par AAO\_rate*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.3473 | 0.5556 |
| **Test du rapport de vraisemblance** | 1 | 0.3505 | 0.5538 |
| **Khi-2 continuité ajustée** | 1 | 0.1482 | 0.7003 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.3446 | 0.5572 |
| **Coefficient Phi** |  | 0.0519 |  |
| **Coefficient de contingence** |  | 0.0518 |  |
| **V de Cramer** |  | 0.0519 |  |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 22 |
| **Pr <= F unilatérale à gauche** | 0.7854 |
| **Pr >= F unilatérale à droite** | 0.3525 |
|  |  |
| **Probabilité de la table (P)** | 0.1379 |
| **Pr <= P bilatéral** | 0.6834 |

|  |
| --- |
| ***Taille de l'échantillon = 129*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Adequate occlusion rate at 6 months(Raymond score)** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | No | 22 (28.2%) | 12 (23.5%) | 34 (26.4%) |
|  | Yes | 56 (71.8%) | 39 (76.5%) | 95 (73.6%) |
|  | 95% CI | 61.8% - 81.8% | 64.8% - 88.1% | 66% - 81.2% |
|  | Between group test |  |  | 0.556 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par AAO\_rateb** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **AAO\_rateb(Adequate occlusion rate at 6 months(OKM score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 8 18.60 28.57 66.67 | 20 46.51 71.43 64.52 | 28 65.12 |
| **FRED X** | 4 9.30 26.67 33.33 | 11 25.58 73.33 35.48 | 15 34.88 |
| **Total** | 12 27.91 | 31 72.09 | 43 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par AAO\_rateb*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.0176 | 0.8944 |
| **Test du rapport de vraisemblance** | 1 | 0.0177 | 0.8942 |
| **Khi-2 continuité ajustée** | 1 | 0.0000 | 1.0000 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.0172 | 0.8956 |
| **Coefficient Phi** |  | 0.0202 |  |
| **Coefficient de contingence** |  | 0.0202 |  |
| **V de Cramer** |  | 0.0202 |  |
| **WARNING: 25% des cellules ont un effectif théorique inférieur à 5. Le test du Khi-2 peut ne pas convenir.** | | | |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 8 |
| **Pr <= F unilatérale à gauche** | 0.6823 |
| **Pr >= F unilatérale à droite** | 0.5943 |
|  |  |
| **Probabilité de la table (P)** | 0.2766 |
| **Pr <= P bilatéral** | 1.0000 |

|  |
| --- |
| ***Taille de l'échantillon = 43*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Adequate occlusion rate at 6 months(OKM score)** | N | 28 |  | 28 |
|  | Missing data | 50 | 36 | 86 |
|  | No | 8 (28.6%) | 4 (26.7%) | 12 (27.9%) |
|  | Yes | 20 (71.4%) | 11 (73.3%) | 31 (72.1%) |
|  | 95% CI | 54.7% - 88.2% | 51.0% - 95.7% | 58.7% - 85.5% |
|  | Between group test |  |  | 1.000 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Occlusion degree (Raymond-Roy score) at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm occlusion degree** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | Obliteration | 51 (65.4%) | 35 (68.6%) | 86 (66.7%) |
|  | Residual neck | 5 (6.4%) | 4 (7.8%) | 9 (7.0%) |
|  | Residual aneurysm | 17 (21.8%) | 9 (17.6%) | 26 (20.2%) |
|  | Cannot be assessed from the imaging | 5 (6.4%) | 3 (5.9%) | 8 (6.2%) |
|  | Between group test |  |  | 0.948 (Fisher) |
|  |  |  |  |  |
| **6M : Aneurysm occlusion degree specification** | N | 7 |  | 7 |
|  | Missing data | 71 | 44 | 115 |
|  | Class IIIa | 0 | 5 (71.4%) | 5 (35.7%) |
|  | Class IIIb | 7 (100.0%) | 2 (28.6%) | 9 (64.3%) |

**FRITS**

**EFFICACY**

**Table : Aneurysm filling at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm filling** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | A: total filling (>95%) | 4 (5.1%) | 2 (3.9%) | 6 (4.7%) |
|  | B: subtotal filling (5-95%) | 5 (6.4%) | 6 (11.8%) | 11 (8.5%) |
|  | C: entry remnant (<5%) | 1 (1.3%) |  | 1 (0.8%) |
|  | D: no filling (0%) | 19 (24.4%) | 11 (21.6%) | 30 (23.3%) |
|  | Cannot be assessed from the imaging | 49 (62.8%) | 30 (58.8%) | 79 (61.2%) |
|  | Not applicable | 0 | 2 (3.9%) | 2 (1.6%) |
|  | Between group test |  |  | 0.463 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Aneurysm Occlusion stability at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm Occlusion stability** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | Better | 42 (53.8%) | 30 (58.8%) | 72 (55.8%) |
|  | Same | 10 (12.8%) | 6 (11.8%) | 16 (12.4%) |
|  | Cannot be assessed from the imaging | 26 (33.3%) | 15 (29.4%) | 41 (31.8%) |
|  | Between group test |  |  | 0.855 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Stasis phase at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Stasis phase** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | 1: no stasis (arterial phase clearance, before capillary phase) | 1 (1.3%) | 1 (2.0%) | 2 (1.6%) |
|  | 2: moderate stasis (clearance before venous phase) | 4 (5.1%) |  | 4 (3.1%) |
|  | 3: significant stasis (persistent contrast at venous phase) | 5 (6.4%) | 4 (7.8%) | 9 (7.0%) |
|  | Cannot be assessed from the imaging | 39 (50.0%) | 18 (35.3%) | 57 (44.2%) |
|  | Not applicable | 29 (37.2%) | 28 (54.9%) | 57 (44.2%) |
|  | Between group test |  |  | 0.135 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Aneurysm sac size change at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm sac size change** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | Stable | 26 (33.3%) | 16 (31.4%) | 42 (32.6%) |
|  | Decreased sac size | 15 (19.2%) | 13 (25.5%) | 28 (21.7%) |
|  | Cannot be assessed from the imaging | 37 (47.4%) | 22 (43.1%) | 59 (45.7%) |
|  | Between group test |  |  | 0.698 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Stent Stability at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Stent Stability** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | Yes | 46 (59.0%) | 33 (64.7%) | 79 (61.2%) |
|  | Cannot be assessed from the imaging | 32 (41.0%) | 18 (35.3%) | 50 (38.8%) |
|  | Between group test |  |  | 0.514 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Stent covering the neck at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Stent covering the neck** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | No | 1 (1.3%) |  | 1 (0.8%) |
|  | Yes | 47 (60.3%) | 32 (62.7%) | 79 (61.2%) |
|  | Cannot be assessed from the imaging | 30 (38.5%) | 19 (37.3%) | 49 (38.0%) |
|  | Between group test |  |  | 1.000 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Parent artery permeability at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Parent Artery permeability** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | No stenosis | 16 (20.5%) | 12 (23.5%) | 28 (21.7%) |
|  | Stenosis < 50% | 7 (9.0%) | 6 (11.8%) | 13 (10.1%) |
|  | On MRA or CTA images, no stenosis or Stenosis < 50% | 51 (65.4%) | 26 (51.0%) | 77 (59.7%) |
|  | Stenosis >= 50 % | 0 | 1 (2.0%) | 1 (0.8%) |
|  | Complete occlusion | 1 (1.3%) | 1 (2.0%) | 2 (1.6%) |
|  | On MRA or CTA images, Stenosis >= 50 % or complete occlusion | 2 (2.6%) | 2 (3.9%) | 4 (3.1%) |
|  | Cannot be assessed from the imaging | 1 (1.3%) | 3 (5.9%) | 4 (3.1%) |
|  | Between group test |  |  | 0.447 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Retreatment rate at 6 months (CORELAB) [ITT - N=129 patients]**

|  | | **FRED / FRED Jr N=78** | **FRED X N=51** | **Total N=129** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Retreatment** | N | 78 |  | 78 |
|  | Missing data | 0 |  | 0 |
|  | No | 78 (100.0%) | 51 (100.0%) | 129 (100.0%) |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par ACO\_rate** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **ACO\_rate(Aneurysm complete occlusion rate at 6 months(Raymond score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 25 21.37 35.71 62.50 | 45 38.46 64.29 58.44 | 70 59.83 |
| **FRED X** | 15 12.82 31.91 37.50 | 32 27.35 68.09 41.56 | 47 40.17 |
| **Total** | 40 34.19 | 77 65.81 | 117 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par ACO\_rate*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.1804 | 0.6710 |
| **Test du rapport de vraisemblance** | 1 | 0.1811 | 0.6704 |
| **Khi-2 continuité ajustée** | 1 | 0.0511 | 0.8212 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.1789 | 0.6723 |
| **Coefficient Phi** |  | 0.0393 |  |
| **Coefficient de contingence** |  | 0.0392 |  |
| **V de Cramer** |  | 0.0393 |  |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 25 |
| **Pr <= F unilatérale à gauche** | 0.7325 |
| **Pr >= F unilatérale à droite** | 0.4123 |
|  |  |
| **Probabilité de la table (P)** | 0.1448 |
| **Pr <= P bilatéral** | 0.6961 |

|  |
| --- |
| ***Taille de l'échantillon = 117*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Aneurysm complete occlusion rate at 6 months(Raymond score)** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | No | 25 (35.7%) | 15 (31.9%) | 40 (34.2%) |
|  | Yes | 45 (64.3%) | 32 (68.1%) | 77 (65.8%) |
|  | 95% CI | 53.1% - 75.5% | 54.8% - 81.4% | 57.2% - 74.4% |
|  | Between group test |  |  | 0.671 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par ACO\_rateb** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **ACO\_rateb(Aneurysm complete occlusion rate at 6 months(OKM score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 8 21.62 34.78 72.73 | 15 40.54 65.22 57.69 | 23 62.16 |
| **FRED X** | 3 8.11 21.43 27.27 | 11 29.73 78.57 42.31 | 14 37.84 |
| **Total** | 11 29.73 | 26 70.27 | 37 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par ACO\_rateb*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.7429 | 0.3887 |
| **Test du rapport de vraisemblance** | 1 | 0.7648 | 0.3818 |
| **Khi-2 continuité ajustée** | 1 | 0.2412 | 0.6234 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.7228 | 0.3952 |
| **Coefficient Phi** |  | 0.1417 |  |
| **Coefficient de contingence** |  | 0.1403 |  |
| **V de Cramer** |  | 0.1417 |  |
| **WARNING: 25% des cellules ont un effectif théorique inférieur à 5. Le test du Khi-2 peut ne pas convenir.** | | | |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 8 |
| **Pr <= F unilatérale à gauche** | 0.8927 |
| **Pr >= F unilatérale à droite** | 0.3160 |
|  |  |
| **Probabilité de la table (P)** | 0.2087 |
| **Pr <= P bilatéral** | 0.4766 |

|  |
| --- |
| ***Taille de l'échantillon = 37*** |

**FRITS**

**EFFICACY**

**Table : Aneurysm complete occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Aneurysm complete occlusion rate at 6 months(OKM score)** | N | 23 |  | 23 |
|  | Missing data | 47 | 33 | 80 |
|  | No | 8 (34.8%) | 3 (21.4%) | 11 (29.7%) |
|  | Yes | 15 (65.2%) | 11 (78.6%) | 26 (70.3%) |
|  | 95% CI | 45.8% - 84.7% | 57.1% - 100.0% | 55.5% - 85% |
|  | Between group test |  |  | 0.477 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par AAO\_rate** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **AAO\_rate(Adequate occlusion rate at 6 months(Raymond score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 21 17.95 30.00 65.63 | 49 41.88 70.00 57.65 | 70 59.83 |
| **FRED X** | 11 9.40 23.40 34.38 | 36 30.77 76.60 42.35 | 47 40.17 |
| **Total** | 32 27.35 | 85 72.65 | 117 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par AAO\_rate*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.6157 | 0.4327 |
| **Test du rapport de vraisemblance** | 1 | 0.6231 | 0.4299 |
| **Khi-2 continuité ajustée** | 1 | 0.3285 | 0.5666 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.6104 | 0.4346 |
| **Coefficient Phi** |  | 0.0725 |  |
| **Coefficient de contingence** |  | 0.0723 |  |
| **V de Cramer** |  | 0.0725 |  |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 21 |
| **Pr <= F unilatérale à gauche** | 0.8404 |
| **Pr >= F unilatérale à droite** | 0.2850 |
|  |  |
| **Probabilité de la table (P)** | 0.1253 |
| **Pr <= P bilatéral** | 0.5273 |

|  |
| --- |
| ***Taille de l'échantillon = 117*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Adequate occlusion rate at 6 months(Raymond score)** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | No | 21 (30.0%) | 11 (23.4%) | 32 (27.4%) |
|  | Yes | 49 (70.0%) | 36 (76.6%) | 85 (72.6%) |
|  | 95% CI | 59.3% - 80.7% | 64.5% - 88.7% | 64.6% - 80.7% |
|  | Between group test |  |  | 0.433 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  |
| --- |
| ***La procédure FREQ*** |

| **Table de fgroup par AAO\_rateb** | | | |
| --- | --- | --- | --- |
| **fgroup(Subgroup device)** | **AAO\_rateb(Adequate occlusion rate at 6 months(OKM score))** | | |
| **Fréquence Pourcentage Pct de ligne Pct de col.** | **No** | **Yes** | **Total** |
| **FRED / FRED Jr** | 8 21.62 34.78 72.73 | 15 40.54 65.22 57.69 | 23 62.16 |
| **FRED X** | 3 8.11 21.43 27.27 | 11 29.73 78.57 42.31 | 14 37.84 |
| **Total** | 11 29.73 | 26 70.27 | 37 100.00 |

|  |
| --- |
| ***Statistiques pour la table de fgroup par AAO\_rateb*** |

| **Statistique** | **DDL** | **Valeur** | **Prob** |
| --- | --- | --- | --- |
| **Khi-2** | 1 | 0.7429 | 0.3887 |
| **Test du rapport de vraisemblance** | 1 | 0.7648 | 0.3818 |
| **Khi-2 continuité ajustée** | 1 | 0.2412 | 0.6234 |
| **Khi-2 de Mantel-Haenszel** | 1 | 0.7228 | 0.3952 |
| **Coefficient Phi** |  | 0.1417 |  |
| **Coefficient de contingence** |  | 0.1403 |  |
| **V de Cramer** |  | 0.1417 |  |
| **WARNING: 25% des cellules ont un effectif théorique inférieur à 5. Le test du Khi-2 peut ne pas convenir.** | | | |

| **Test exact de Fisher** | |
| --- | --- |
| **Cellule (1,1) Fréquence (F)** | 8 |
| **Pr <= F unilatérale à gauche** | 0.8927 |
| **Pr >= F unilatérale à droite** | 0.3160 |
|  |  |
| **Probabilité de la table (P)** | 0.2087 |
| **Pr <= P bilatéral** | 0.4766 |

|  |
| --- |
| ***Taille de l'échantillon = 37*** |

**FRITS**

**EFFICACY**

**Table : Adequate occlusion rate at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Adequate occlusion rate at 6 months(OKM score)** | N | 23 |  | 23 |
|  | Missing data | 47 | 33 | 80 |
|  | No | 8 (34.8%) | 3 (21.4%) | 11 (29.7%) |
|  | Yes | 15 (65.2%) | 11 (78.6%) | 26 (70.3%) |
|  | 95% CI | 45.8% - 84.7% | 57.1% - 100.0% | 55.5% - 85% |
|  | Between group test |  |  | 0.477 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Occlusion degree (Raymond-Roy score) at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm occlusion degree** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | Obliteration | 45 (64.3%) | 32 (68.1%) | 77 (65.8%) |
|  | Residual neck | 4 (5.7%) | 4 (8.5%) | 8 (6.8%) |
|  | Residual aneurysm | 17 (24.3%) | 8 (17.0%) | 25 (21.4%) |
|  | Cannot be assessed from the imaging | 4 (5.7%) | 3 (6.4%) | 7 (6.0%) |
|  | Between group test |  |  | 0.762 (Fisher) |
|  |  |  |  |  |
| **6M : Aneurysm occlusion degree specification** | N | 7 |  | 7 |
|  | Missing data | 63 | 40 | 103 |
|  | Class IIIa | 0 | 5 (71.4%) | 5 (35.7%) |
|  | Class IIIb | 7 (100.0%) | 2 (28.6%) | 9 (64.3%) |

**FRITS**

**EFFICACY**

**Table : Aneurysm filling at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm filling** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | A: total filling (>95%) | 4 (5.7%) | 2 (4.3%) | 6 (5.1%) |
|  | B: subtotal filling (5-95%) | 5 (7.1%) | 5 (10.6%) | 10 (8.5%) |
|  | D: no filling (0%) | 15 (21.4%) | 11 (23.4%) | 26 (22.2%) |
|  | Cannot be assessed from the imaging | 46 (65.7%) | 27 (57.4%) | 73 (62.4%) |
|  | Not applicable | 0 | 2 (4.3%) | 2 (1.7%) |
|  | Between group test |  |  | 0.466 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Aneurysm Occlusion stability at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm Occlusion stability** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | Better | 36 (51.4%) | 28 (59.6%) | 64 (54.7%) |
|  | Same | 9 (12.9%) | 6 (12.8%) | 15 (12.8%) |
|  | Cannot be assessed from the imaging | 25 (35.7%) | 13 (27.7%) | 38 (32.5%) |
|  | Between group test |  |  | 0.637 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Stasis phase at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Stasis phase** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | 1: no stasis (arterial phase clearance, before capillary phase) | 1 (1.4%) | 1 (2.1%) | 2 (1.7%) |
|  | 2: moderate stasis (clearance before venous phase) | 3 (4.3%) |  | 3 (2.6%) |
|  | 3: significant stasis (persistent contrast at venous phase) | 5 (7.1%) | 3 (6.4%) | 8 (6.8%) |
|  | Cannot be assessed from the imaging | 36 (51.4%) | 17 (36.2%) | 53 (45.3%) |
|  | Not applicable | 25 (35.7%) | 26 (55.3%) | 51 (43.6%) |
|  | Between group test |  |  | 0.170 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Aneurysm sac size change at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Aneurysm sac size change** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | Stable | 22 (31.4%) | 15 (31.9%) | 37 (31.6%) |
|  | Decreased sac size | 14 (20.0%) | 12 (25.5%) | 26 (22.2%) |
|  | Cannot be assessed from the imaging | 34 (48.6%) | 20 (42.6%) | 54 (46.2%) |
|  | Between group test |  |  | 0.737 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Stent Stability at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Stent Stability** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | Yes | 41 (58.6%) | 32 (68.1%) | 73 (62.4%) |
|  | Cannot be assessed from the imaging | 29 (41.4%) | 15 (31.9%) | 44 (37.6%) |
|  | Between group test |  |  | 0.298 (Chi-2) |

**FRITS**

**EFFICACY**

**Table : Stent covering the neck at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Stent covering the neck** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | No | 1 (1.4%) |  | 1 (0.9%) |
|  | Yes | 41 (58.6%) | 31 (66.0%) | 72 (61.5%) |
|  | Cannot be assessed from the imaging | 28 (40.0%) | 16 (34.0%) | 44 (37.6%) |
|  | Between group test |  |  | 0.737 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Parent artery permeability at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Parent Artery permeability** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | No stenosis | 13 (18.6%) | 11 (23.4%) | 24 (20.5%) |
|  | Stenosis < 50% | 6 (8.6%) | 6 (12.8%) | 12 (10.3%) |
|  | On MRA or CTA images, no stenosis or Stenosis < 50% | 48 (68.6%) | 23 (48.9%) | 71 (60.7%) |
|  | Stenosis >= 50 % | 0 | 1 (2.1%) | 1 (0.9%) |
|  | Complete occlusion | 1 (1.4%) | 1 (2.1%) | 2 (1.7%) |
|  | On MRA or CTA images, Stenosis >= 50 % or complete occlusion | 2 (2.9%) | 2 (4.3%) | 4 (3.4%) |
|  | Cannot be assessed from the imaging | 0 | 3 (6.4%) | 3 (2.6%) |
|  | Between group test |  |  | 0.130 (Fisher) |

**FRITS**

**EFFICACY**

**Table : Retreatment rate at 6 months (CORELAB) [PP - N=117 patients]**

|  | | **FRED / FRED Jr N=70** | **FRED X N=47** | **Total N=117** |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **6M : Retreatment** | N | 70 |  | 70 |
|  | Missing data | 0 |  | 0 |
|  | No | 70 (100.0%) | 47 (100.0%) | 117 (100.0%) |